MASCT by Hengrui Yuanzheng Biotechnology for Metastatic Colorectal Cancer: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.

Links to presentation and webcast – Biotech Investments

Sartorius Stedim Biotech SA / Key word(s): Miscellaneous Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast 17-May-2024 / 19:32 CET/CEST Aubagne, France |

May 18, 2024

Surgeons slow to adopt new biomaterials for bone defects

Two million bone transplants are performed worldwide yearly, including half a million in the United States alone. Yet, a QUT-led study has found surgeons are

December 19, 2024

Everyone in digital health wants to get to profitability. Hims has done it

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Digital health company Hims & Hers has

February 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.